Nurix Therapeutics, Inc. (NasdaqGM: NRIX)
Health Care · Biotechnology · US
$22.06
-1.32% today · +129.9% 1Y
Nurix Therapeutics, Inc. (NasdaqGM: NRIX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.32B and employs 317 people.
Over the last twelve months the share price has gained 129.9%, trading between 9.00 and 28.23.
Tweenvest scores Nurix Therapeutics, Inc. across four factors: quality 37/100, value 64/100, growth 100/100. Its strongest factor is growth.
NRIX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.32B
- Revenue (TTM)
- $36.77M
- P/E
- —
- EPS
- -3.41
- Dividend yield
- —
- Beta (5Y)
- 1.82
- 52-week high
- $28.23
- 52-week low
- $9.00
- Avg volume (3M)
- —
- Shares outstanding
- 103.78M
- Employees
- 317
- Next earnings
- —
About Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
- ISIN
- US67080M1036
- Founded
- 2009
- Listed since
- Jul 24, 2020
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Celldex Therapeutics, Inc.NasdaqCM: CLDX | $2.35B | $29.50 | -1.30% |
| Recursion Pharmaceuticals, Inc.NasdaqGS: RXRX | $2.34B | $3.95 | -9.52% |
| PharmaResearch Co., Ltd.KOSDAQ: A214450 | $2.34B | ₩302,500.00 | -1.14% |
| ADMA Biologics, Inc.NasdaqGM: ADMA | $2.32B | $10.29 | -0.68% |
| CanSino Biologics Inc.SEHK: 6185 | $2.27B | HK$35.02 | +1.10% |
| Shenzhen Kangtai Biological Products Co., Ltd.SZSE: 300601 | $2.24B | CN¥13.44 | -1.03% |
| Immunome, Inc.NasdaqCM: IMNM | $2.22B | $19.41 | -0.72% |
| Aurinia Pharmaceuticals Inc.NasdaqGM: AUPH | $2.22B | $16.68 | +0.18% |
Figures last refreshed Oct 11, 2026.